SPTX.US Seaport Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
18.17 USD
Close of Nov 18, 2026
14.85 28.38
Market cap
USD 973M
P/E
-
P/B
2.58x
ROE
-38.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is SPTX.US undervalued?

Graham number

The Graham number of Seaport Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Seaport Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Seaport Therapeutics, Inc. Common Stock yet.

Seaport Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolo…

Full company profile